Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
KDA Group Inc. ( (TSE:KDA) ) has shared an update.
KDA Group Inc. has entered into a non-material collaboration with AstraZeneca Canada to integrate new clinical alerts into its Medherize digital platform in support of next-generation sequencing (NGS) testing for metastatic breast cancer patients at Hôpital du Saint-Sacrement in Quebec City. The project, which can be extended for up to three years if successful, will embed targeted digital notifications within Medherize—already integrated with the Québec Health Record—to prompt timely ordering, interpretation and follow-up of genomic tests, reinforcing the consistent adoption of precision oncology practices and aligning with Quebec’s new framework for community pharmacists managing oral anticancer medications. By connecting clinicians and pharmacists to laboratory data, clinical alerts and patient-reported adverse events in a single workflow, the initiative is intended to speed the path from advanced diagnostics to treatment decisions and is designed as a scalable model that can be replicated across other institutions in Quebec, elsewhere in Canada and internationally, and ultimately extended to other cancer types and emerging targeted therapies.
More about KDA Group Inc.
KDA Group Inc., based in Quebec, is a provider of technological innovations and specialized SaaS software solutions for healthcare professionals, with a strong presence in the pharmaceutical and medical sectors. Its platforms are designed to accelerate the digital transformation of healthcare by improving clinical workflows and information access for Canadian and international markets.
Average Trading Volume: 67,024
Technical Sentiment Signal: Hold
Current Market Cap: C$43.16M
For an in-depth examination of KDA stock, go to TipRanks’ Overview page.